Access submits additional patent applications for Cobalamin-mediated oral medication delivery technology ACCESS PHARMACEUTICALS, INC. , a biopharmaceutical firm leveraging its proprietary drug-delivery platforms to build up treatments in regions of oncology, cancers supportive diabetes and care, announced it has submitted extra patent applications, covering its Cobalamin-mediated oral drug delivery technology formulations of many global best-100 injectable drugs, as a result of the growing curiosity surrounding the company’s proprietary oral delivery technology. ‘The CobOral branding and additional patent filings reflect the high level of interest from partners in our CobOral and CobaCyte medication delivery platforms,’ stated Jeffrey B. Davis, President and CEO, Gain access to Pharmaceuticals, Inc.’ Related StoriesNew RNA check of blood platelets can be used to identify location of cancerStudy shows rare HER2 missense mutations usually do not spread breasts cancer on their ownSausages With Antioxidants From Berries TO AVOID CancerAccess continues to create significant progress using its proprietary CobOral delivery technology.‘This study shows that in addition they struggle more with interest and impulse control,’ Power said. ‘It also emphasizes the importance of evaluating children for ADHD with regards to peers of similar gender and age.’ Needlessly being medication for ADHD may contribute to other problems. Stimulant medications used to treat ADHD have been linked with a reduced appetite in children, sleep issues, tics, and in rare circumstances, cardiovascular or psychiatric problems. A federal study this past year found risks for coronary attack however, stroke, and sudden loss of life among kids taking ADHD medicine were no greater than kids who didn’t consider the drugs, HealthPopreported.